Fig. 5: TIM3-ProIL2V2 activates and expands TIM3− CD8+T cells to overcome PD-1 resistance.
From: TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8+T cell exhaustion

A–F MC38 tumor-bearing female C57BL/6 mice (n = 6/group) were treated with 10 μg TIM3-ProIL2V2 or TIM3-IL2V2-MMPs-Rα on day 16. After 3 days, mice were intraperitoneally injected with 50 μl of brefeldin A solution (BFA, 5 mg/ml). Six hours later, the mice were sacrificed and tumor tissues were collected, and FACS analysis was performed. The number of intratumoral total CD8+T cells/TIM3+ CD8+T cells and TIM3−CD8+T cells (A), IFN-γ+CD8+T cells (B), IFN-γ+TIM3−CD8+ T cells (C), and PD-1+TIM3−TCF1+CD8+ T cells (F) were measured by flow cytometric analysis. The percentage of IFN-γ+ (D) and Ki67+ (E) in TIM3−CD8+T cells were measured by flow cytometric analysis. G, H MC38-OVA tumor-bearing female C57BL/6 mice (n = 6/group) were treated with 10 μg TIM3-ProIL2V2 on day 16 after tumor inoculation. The mice were sacrificed and tumor tissues were collected 72 h after the first injection. The number of OVA-specific CD8+ T cells were measured by flow cytometric analysis. I–K MC38 tumor-bearing female CD45.2+ Havcr2−/− mice (n = 6/group) were transferred with 2 × 106 CD45.1+ Havcr2wt/wt T cells on day 2 after tumor inoculation, followed by treatment with TIM3-ProIL2V2 or PBS on day 12 after tumor inoculation. The mice were sacrificed and tumor tissues were collected 72 h after TIM3-ProIL2V2 treatment. The number of intratumoral CD45.1−TIM3−CD8+ T cells (I) and IFN-γ+CD45.1−TIM3−CD8+ T cells (K) were measured by flow cytometric analysis. The percentage of Ki67+ (J) in CD45.1-TIM3−CD8+ T cells were measured by flow cytometric analysis. L, M B16F10 bearing female C57BL/6 mice (n = 8/group) were i.p. treated with 25 μg TIM3-ProIL2V2 and/or 150 μg anti-PD-L1 twice on day 10 and 13 after tumor inoculation. Tumor volume (G) was measured as indicated and the mouse survival curve was shown in (H). N B16F10 bearing female C57BL/6 mice were treated with TIM3-ProIL2V2 and anti-PD-L1. 30 days after treatment, cured mice (n = 5/group) were re-challenged with 2 × 106 B16F10 cells. Data are shown as mean ± SEM and representative of two to three independent experiments. P value was determined by unpaired two-tailed t tests (A–L, N). Statistical analysis of survival curve was compared using a log-rank test (M).